Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market

Aug

27
2014

US CONTACT: (732) 993-9821
CHINA CONTACT: +86-512-6745-1085 ext 101
info@amerigenpharma.com


Lyndhurst NJ, USA and Ningbo, China, August 27, 2014 – Amerigen Pharmaceuticals Limited (“Amerigen”) and the Ningbo Menovo Pharmaceutical Co., Ltd, (“Menovo”) today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market. Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be responsible for manufacturing API and finished product whereas Amerigen will be responsible for clinical, regulatory and commercial activities in the United States. Amerigen will also provide support and assistance to Menovo in obtaining United States Food and Drug Administration (“FDA”) approval for their finished dose manufacturing site in Daxie, China.

Commenting on the deal, John Lowry, Amerigen’s President & CEO, said “This collaboration enables each party to leverage its respective strengths and will broaden Amerigen’s product pipeline. Our first product opportunity leverages formulation work already undertaken by Amerigen at its Suzhou facility and Menovo’s leading position with the corresponding API.”

Adam Yao, Menovo’s CEO, added “By partnering with Amerigen, who is an existing supplier of finished product from China into the United States market from their US FDA and CFDA approved facility in Suzhou, we look forward to accelerating our strategic objective of growing our international business in API’s and integrating this into self-manufactured finished product of the highest quality”.


About

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group’s Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA’s with the US FDA and the Chinese CFDA. Amerigen’s focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen’s products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.